参考文献/References:
[1] Whitehead MT, Wien M, Lee B, et al. Black toenail sign in MELAS syndrome[J]. Pediatr Neurol, 2017, 75(10): 61-65.
[2] El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treatment of MELAS syndrome[J]. J Inborn Errors Metab Screen, 2017, 5: 1-5.
[3] Ohsawa Y, Hagiwara H, Nishimatsu S, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial[J]. J Neurol Neurosurg Psychiatry, 2019, 90(5): 529-536.
[4] El-Hattaba W. MELAS syndrome:Clinical manifestations,pathogenesis,and treatment options[J]. Mol Genet Metab, 2015, 116(1/2): 4-12.
[5] Finsterer J. Rare phenotypic manifestations of MELAS[J]. Yonsei Med J, 2020, 61(10): 904-906.
[6] Koga Y, Povalko N, Inoue E, et al. Therapeutic regimen of l-arginine for MELAS: 9-year, prospective, multicenter, clinical research[J]. J Neurol, 2018, 265(12): 2861-2874.
[7] Pia S, Lui F.Melas syndrome[Z],2021:30422554.
[8] Bhatia KD, Krishnan P, Kortman H, et al. Acute cortical lesions in MELAS syndrome: anatomic distribution, symmetry, and evolution[J]. AJNR Am J Neuroradiol, 2020, 41(1): 167-173.
[9] Chen WT, Lin YS, Yf W, et al. Adult onset MELAS Syndrome Presenting as A Mimic of Herpes Simplex Encephalitis[J]. Acta Neurol Taiwan, 2019, 28(2): 46-51.
[10] Handzel O, Ungar OJ, Lee DJ, et al. Temporal bone histopathology in MELAS syndrome[J]. Laryngoscope Investig Otolaryngol, 2020, 5(1): 152-156.
[11] Hovsepian D, Galati A, Chong RA, et al. MELAS: monitoring treatment with magnetic resonance spectroscopy[J]. Acta Neurol Scand, 2019, 139(1): 82-85.
[12] Hirano M, Emmanuele V, Quinzii CM. Emerging therapies for mitochondrial diseases[J]. Essays Biochem, 2018, 62(3): 467-481.
[13] Doppler C, Kabbasch C, Fink GR, et al. Rapid alterations in Mr imaging in MELAS syndrome[J]. Pract Neurol, 2019, 19(5): 447-448.
[14] Malhotra K, Liebeskind DS. Imaging of MELAS[J]. Curr Pain Headache Rep, 2016, 20(9): 54.
[15] Koenig MK, Emrick L, Karaa A, et al. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes[J]. JAMA Neurol, 2016, 73(5): 591-594.
[16] Ko A, Lee YM. Magnetic resonance spectroscopy in Leigh-MELAS overlap syndrome[J]. World J Pediatr, 2019, 15(3): 306-308.
[17] Sun XR, Jiang GH, Ju XY, et al. MELAS and macroangiopathy A case report and literature review[J]. Medicine(Baltimore), 2018, 97(52): e13866.
[18] 袁云.中国线粒体脑肌病伴高乳酸血症和卒中样发作的诊治专家共识[J].中华神经科杂志,2020,53(3):171-172.
[19] Finsterer J. Rhabdomyolysis in MELAS May be multifactorial[J]. Rinsho Shinkeigaku, 2017, 57(7): 399.
[20] Finsterer J, Zarrouk-Mahjoub S. Epilepsy in MELAS[J]. Pediatr Neurol, 2017, 67: e7-e8.
[21] Deng J, Lu Y, Xie Z, et al. RNA-seq profiling, and impaired autophagic process in skeletal muscle of MELAS[J]. Biochem Biophys Res Commun, 2020, 523(1): 91-97.